JAB 30000
Alternative Names: JAB-30000Latest Information Update: 30 Mar 2022
At a glance
- Originator Jacobio Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Tumour suppressor protein p53 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 25 Mar 2022 JAB 30000 is available for licensing as of 25 Mar 2022. http://en.jacobiopharma.com/blank3.html?introId=23
- 22 Mar 2022 Early research in Solid tumours in China (PO), prior to March 2022
- 22 Mar 2022 Jacobio Pharmaceuticals plans to file IND for Solid tumours, during 2023 to 2024 (Jacobio Pharmaceuticals pipeline, March 2022)